View Older Stories View More Recent Stories
-
Leerink Partners Downgrades Johnson & Johnson (JNJ) to Market Perform
-
Johnson & Johnson (JNJ) reports Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis
-
Johnson & Johnson (JNJ) call put ratio 1 call to 1.5 puts
-
Johnson & Johnson (JNJ) says TREMFYA positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks
-
Johnson & Johnson (JNJ) says TREMFYA delivered sustained clinical and endoscopic remission in ulcerative colitis through two years
-
Goldman Updating US May Directors' Cut Conviction List Names
-
Johnson & Johnson (JNJ) receives FDA approval for IMAAVY
-
HSBC cuts biotech stocks: Eli Lilly lowered to Reduce
-
Medtech Q1 earnings preview: Potential tariff exposure
-
Johnson & Johnson (JNJ) unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA
-
TD Cowen: 'Johnson & Johnson (JNJ) Is Prepared to Absorb Tariff Costs'
-
UBS Reiterates Buy Rating on Johnson & Johnson (JNJ)
-
Johnson & Johnson (JNJ) Tops Q1 EPS by 19c; adjusts forecast
-
Johnson & Johnson (JNJ) Raises Quarterly Dividend 4.8% to $1.30; 3.4% Yield
-
Analysts brace for volatile Johnson & Johnson Q1 amid Part D impact, legal setbacks
-
Johnson & Johnson (JNJ) call put ratio 1 call to 1.4 puts into quarter results
-
Johnson & Johnson (JNJ) call put ratio 1 call to 1.3 puts into quarter results
-
Pharma stocks slide after Trump signals tariffs on sector
-
Johnson & Johnson (JNJ) highlights new data that showcase the strength of nipocalimab
-
Goldman Sachs Upgrades Johnson & Johnson (JNJ) to Buy
-
UBS Reiterates Buy Rating on Johnson & Johnson (JNJ)
-
Johnson & Johnson (JNJ) announces TREMFYA significantly reduced both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis
-
RBC Capital Assesses U.S. Tariff Impact Across Industries
-
RBC Capital on Johnson & Johnson (JNJ): '$5B Opportunity is Progressing'
-
What's next for Johnson and Johnson after third failed attempt to settle talc laws
-
Johnson & Johnson (JNJ) Closes Intra-Cellular Therapies, Inc. (ITCI) Acquisition
-
Johnson & Johnson (JNJ) Sets April 2nd as Expected Closing Date for Intra-Cellular Acquisition
-
Federal Judge Rejects Johnson & Johnson (JNJ) Bankruptcy Strategy
-
TD Cowen on Johnson & Johnson (JNJ): 'TALC Settlement Plan Hits Setback'
-
UBS Reiterates Buy Rating on Johnson & Johnson (JNJ)
-
Johnson & Johnson (JNJ) unit ordered to pay $1.64 billion in HIV drug marketing case
-
Johnson & Johnson (JNJ): RYBREVANT plus LAZCLUZE outperforms osimertinib with a significant and unprecedented OS benefit in patients with EGFR-mutated NSCLC
-
Johnson & Johnson (JNJ) presents new nipocalimab data and real-world research
-
Tevogen Bio (TVGN) Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan
-
Investment commitments in U.S. nears $3 trillion since Trump took office
-
J&J is latest company trying to get on Trump's good side with big U.S. investment
-
J&J is latest company trying to get on Trump's good side with big U.S. investment
-
Johnson & Johnson (JNJ) Increases U.S. Investment to More than $55B Over the Next Four Years
-
Johnson & Johnson (JNJ) Announces RYBREVANT plus LAZCLUZE significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025
-
Johnson & Johnson (JNJ): Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren'
-
How could tariffs shake up the pharma sector?
-
RBC Capital on Johnson & Johnson (JNJ): 'Icotrokinra's +$5B Opportunity is Progressing'
-
Johnson & Johnson (JNJ): Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients
-
Guggenheim Downgrades Neumora Therapeutics (NMRA) to Neutral
-
Guggenheim Reiterates Buy Rating on Neumora Therapeutics (NMRA), PT $7
-
Johnson & Johnson (JNJ): TREMFYA subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative
-
Biotech Q4 earnings preview: Goldman Sachs
-
Johnson & Johnson (JNJ): New nipocalimab data published in mAbs journal
-
Johnson & Johnson (JNJ) Puts Stroke Care Business Up For Sale - FT
-
Johnson & Johnson (JNJ) PT Raised to $166 at Guggenheim
